TY - JOUR
T1 - Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome
T2 - An open-labeled clinical observation
AU - Omori, Yuki
AU - Kanbayashi, Takashi
AU - Sagawa, Yohei
AU - Imanishi, Aya
AU - Tsutsui, Ko
AU - Takahashi, Yuya
AU - Takeshima, Masahiro
AU - Takaki, Manabu
AU - Nishino, Seiji
AU - Shimizu, Tetsuo
N1 - Funding Information:
Takashi Kanbayashi has received speaker’s honoraria from Otsuka Pharmaceutical, MSD, and Eisai. Manabu Takaki has received speaker’s honoraria from Otsuka Pharmaceutical. Tetsuo Shimizu has received research grants from Eisai and MSD, and speaker’s honoraria from MSD, Takeda Pharmaceutical, Pfizer, and Yoshitomi Pharmaceutical. The authors report no other conflicts of interest in this work.
Publisher Copyright:
© 2018 Omori et al.
PY - 2018/5/18
Y1 - 2018/5/18
N2 - Objectives: Delayed sleep phase syndrome (DSPS) is a chronic dysfunction of circadian rhythm of the subject that impairs functioning in social, occupational, or other spheres. High rate of depression is found among DSPS patients. Aripiprazole (APZ), a second-generation antipsychotic, is effective in treatment of depression as well as schizophrenia. Recently, few case reports show the effectiveness of APZ in treating DSPS and non-24-hour sleep–wake rhythm disorder. Therefore, we tried to treat DSPS with depression using APZ. Methods: Twelve subjects (including four women) aged 19–64 years were included. The subjects were prescribed initially 0.5–3 mg of APZ once a day with subsequent dose adjustments. Results: Sleep onset, midpoint of sleep, and sleep offset were significantly advanced by 1.1, 1.8, and 2.5 hours, respectively. Unexpectedly, sleep duration became significantly shorter by 1.3 hours after treatment. Their depressive moods showed an unremarkable change. Conclusion: Low dose of APZ advanced the sleep rhythm and reduced nocturnal sleep time in the subjects with DSPS. Since it is not easy for physicians to treat prolonged sleep duration often associated with DSPS, this medication would become a new therapeutic option for these patients.
AB - Objectives: Delayed sleep phase syndrome (DSPS) is a chronic dysfunction of circadian rhythm of the subject that impairs functioning in social, occupational, or other spheres. High rate of depression is found among DSPS patients. Aripiprazole (APZ), a second-generation antipsychotic, is effective in treatment of depression as well as schizophrenia. Recently, few case reports show the effectiveness of APZ in treating DSPS and non-24-hour sleep–wake rhythm disorder. Therefore, we tried to treat DSPS with depression using APZ. Methods: Twelve subjects (including four women) aged 19–64 years were included. The subjects were prescribed initially 0.5–3 mg of APZ once a day with subsequent dose adjustments. Results: Sleep onset, midpoint of sleep, and sleep offset were significantly advanced by 1.1, 1.8, and 2.5 hours, respectively. Unexpectedly, sleep duration became significantly shorter by 1.3 hours after treatment. Their depressive moods showed an unremarkable change. Conclusion: Low dose of APZ advanced the sleep rhythm and reduced nocturnal sleep time in the subjects with DSPS. Since it is not easy for physicians to treat prolonged sleep duration often associated with DSPS, this medication would become a new therapeutic option for these patients.
KW - Aripiprazole
KW - Delayed sleep phase syndrome
KW - Total sleep time
UR - http://www.scopus.com/inward/record.url?scp=85048653066&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048653066&partnerID=8YFLogxK
U2 - 10.2147/NDT.S158865
DO - 10.2147/NDT.S158865
M3 - Article
AN - SCOPUS:85048653066
SN - 1176-6328
VL - 14
SP - 1281
EP - 1286
JO - Neuropsychiatric Disease and Treatment
JF - Neuropsychiatric Disease and Treatment
ER -
